Market Overview

UPDATE: Citigroup Lowers PT on Quest Diagnostics Following Disappointing 3Q13 Results

Share:
Related DGX
18 Biggest Mid-Day Gainers For Monday
Benzinga's Top Upgrades
The Most And Least Loved Stocks In The S&P 500 (Seeking Alpha)

In a report published Friday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Quest Diagnostics (NYSE: DGX), but lowered the price target from $64.00 to $60.00.

In the report, Citigroup noted, “DGX previewed disappointing 3Q13 results this morning after mounting a spirited defense of its guidance on its 7/18/13 2Q13 conference call. More recently, on 9/18/13 we hosted a management roadshow in Chicago. The key takeaway from our note was as follows ‘Mgmt is sticking to its 2014 double-digit EPS growth target while maintaining that they've seen no material recent change in industry trends.' Obviously, it's difficult to square these outlooks with the reported results.”

Quest Diagnostics closed on Thursday at $58.66.

Latest Ratings for DGX

DateFirmActionFromTo
Nov 2016UBSUpgradesNeutralBuy
Sep 2016CitigroupInitiates Coverage onNeutral
Aug 2016MizuhoDowngradesBuyNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Citigroup Gary TaylorAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!